-
FROM CLINICAL DEVELOPMENT TO REIMBURSEMENT: REAL WORLD EVIDENCE IS THE MISSING LINK FOR IN VITRO DIAGNOSTICS - A CONCEPTUAL FRAMEWORK
Aug 11, 2026, 17:16 PM -
VARIABILITY AND LACK OF STANDARDIZATION IN PATIENT GLOBAL IMPRESSION (PGI) SCALES IN ONCOLOGY CLINICAL TRIALS (2020-2025)
Aug 11, 2026, 17:16 PM -
A GATEWAY TO FUTURE INNOVATIONS: REAL OPTION VALUE (ROV) OF FIRST-LINE CDK4/6 INHIBITORS IN HR+/HER2-NEGATIVE METASTATIC BREAST CANCER
Aug 11, 2026, 17:16 PM -
COST-UTILITY ANALYSIS OF CLOSED LOOP STIMULATION PACEMAKERS VERSUS CONVENTIONAL RATE-ADAPTIVE PACING IN THE UNITED KINGDOM
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF FOUR FIRST-LINE ANTI-VIRAL TREATMENTS FOR HBEAG-POSITIVE AND HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN CHINA
Aug 11, 2026, 17:16 PM -
WEIGHTING FOR GODOT: WHEN MAICS MOVE THE ESTIMATE BUT NOT THE UNCERTAINTY
Aug 11, 2026, 17:16 PM -
UPTAKE OF THE NICE SEVERITY MODIFIER: WHAT PROPORTION OF APPLICATIONS QUALIFY?
Aug 11, 2026, 17:16 PM -
ESTIMATING THE INPATIENT ECONOMIC BURDEN OF OBESITY IN GREECE: A NATIONWIDE POPULATION ATTRIBUTABLE FRACTION ANALYSIS USING REAL-WORLD HOSPITAL DATA
Aug 11, 2026, 17:16 PM -
THE HIDDEN COST OF ACCESS: INTEGRATING HTA, EVIDENCE GENERATION, AND MANAGED ENTRY AGREEMENT REQUIREMENTS INTO COST-BASED PRICING MODELS FOR CELL AND GENE THERAPIES
Aug 11, 2026, 17:16 PM -
COMPARATIVE EFFICACY, SAFETY, AND NETWORK META-ANALYSIS FEASIBILITY OF IMMUNOTHERAPY-BASED COMBINATION THERAPIES FOR ADVANCED RENAL CELL CARCINOMA: A SYSTEMATIC LITERATURE REVIEW
Aug 11, 2026, 17:16 PM -
REPORTING OF ARTIFICIAL INTELLIGENCE (AI) USE IN NICE CLINICAL GUIDELINES AND TECHNOLOGY APPRAISALS: A STRUCTURED REVIEW
Aug 11, 2026, 17:16 PM -
A HYBRID, MULTI-SOURCE REAL-WORLD EVIDENCE FRAMEWORK FOR POST-AUTHORIZATION STUDIES: DESIGN CONSIDERATIONS FOR EU JOINT CLINICAL ASSESSMENT READINESS
Aug 11, 2026, 17:16 PM -
NAVIGATING UNCERTAINTY IN ONCOLOGY: CONCORDANCE BETWEEN EUROPEAN HTA BODIES AND THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY
Aug 11, 2026, 17:16 PM -
OUTCOMES-BASED AGREEMENTS IN EUROPEAN HTA: NOT A ROUTINE UNCERTAINTY TOOL, BUT A SELECTIVE ACCESS MECHANISM
Aug 11, 2026, 17:16 PM -
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH CHRONIC DISEASES: A TARGETED LITERATURE REVIEW OF THE IMPACT OF CHRONIC DISEASES IN SPAIN AND EUROPE
Aug 11, 2026, 17:16 PM -
REVISITING THE DESIGN OF MANAGED ENTRY AGREEMENTS: A METHODOLOGICAL FRAMEWORK TO STREAMLINE THEIR ADOPTION
Aug 11, 2026, 17:16 PM -
VALUE FRAMEWORK FOR HEALTH TECHNOLOGY ASSESSMENT IN BRAZIL'S SUPPLEMENTARY HEALTH SYSTEM: IDENTIFYING THE KEY DRIVERS OF DECISION-MAKING (2021-2025)
Aug 11, 2026, 17:16 PM -
TRENDS AND DRIVERS FOR IN CANCER DRUGS FUND USE IN NON-SMALL CELL LUNG CANCER
Aug 11, 2026, 17:16 PM -
THE EVOLVING TREATMENT LANDSCAPE OF MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA: APPROVED THERAPIES AND AN EXPANDING LATE-STAGE PIPELINE
Aug 11, 2026, 17:16 PM -
TREATMENT PATTERNS AND DISEASE BURDEN IN CHINESE PATIENTS WITH WHO GRADE 2 ASTROCYTOMA AND OLIGODENDROGLIOMA: A CROSS-SECTIONAL STUDY
Aug 11, 2026, 17:16 PM
